Twinvir Sofosbuvir+Ledipasvir
Offer type: salePublished: 09.02.2018
| Price: | 17 900 RUR |
| Company: | Twinvir |
| Seller: |  Elizaveta Kul'chitskaya |
| Phones: |  +88005118630 Show phone |
| Address: | Russian Federation, Moscow |
Name
Twinvir ™ is a combined antiviral drug. Composition
One tablet Twinvir ™ contains Ladieswear 90 mg and Sofosbuvir 400 mg. Indications for use The combination of Ladieswear and Sofosbuvir is indicated for the treatment of hepatitis C genotype 1, 4, 5 and 6 in adults. Form release
28 tablets, film-coated. Dosage and method of application Recommended dosage: one tablet (Ledipasvir 90 mg and Sofosbuvir 400 mg) administered orally once a day. The recommended duration of treatment for patients without the experience of negative response to treatment: 12 weeks. With the experience of negative treatment response (without cirrhosis): 24 weeks. With the experience of negative treatment response (liver cirrhosis): 24 weeks.
Twinvir ™ is a combined antiviral drug. Composition
One tablet Twinvir ™ contains Ladieswear 90 mg and Sofosbuvir 400 mg. Indications for use The combination of Ladieswear and Sofosbuvir is indicated for the treatment of hepatitis C genotype 1, 4, 5 and 6 in adults. Form release
28 tablets, film-coated. Dosage and method of application Recommended dosage: one tablet (Ledipasvir 90 mg and Sofosbuvir 400 mg) administered orally once a day. The recommended duration of treatment for patients without the experience of negative response to treatment: 12 weeks. With the experience of negative treatment response (without cirrhosis): 24 weeks. With the experience of negative treatment response (liver cirrhosis): 24 weeks.
